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Abstract
Aim: To describe the frequency and number of premonitory symptoms (PS) in migraine, the co-occurrence of different
PS, and their association with migraine-related factors.
Methods: In this cross-sectional study, a validated questionnaire was sent to Finnish migraine families between 2002 and
2013 to obtain data on 14 predefined PS, migraine diagnoses, demographic factors, and migraine characteristics. The
estimated response rate was 80%.
Results: Out of 2714 persons, 2223 were diagnosed with migraine. Among these, 77% reported PS, with a mean
number of 3.0 symptoms compared to 30% (p< 0.001) and 0.5 symptoms (p< 0.001) among 491 persons with non-
migraine headaches. Yawning was the most commonly reported symptom (34%) among migraineurs. Females reported
PS more frequently than males (81 versus 64%, p< 0.001) and experienced a higher number of different symptoms
(mean 3.3 versus 1.8, p< 0.001). All measures of migraine severity were associated with a higher burden of PS. Light and
sound sensitivity showed the highest co-occurrence (kappa¼ 0.51, 95% CI 0.47–0.55). In a generalized linear model, age,
gender, higher frequency, duration and intensity of headache, reduced working capacity, most aura symptoms, and
associated symptoms of the headache phase were significantly associated with an increased in the number of PS.
Conclusion: PS are experienced by a majority of migraineurs. More severe migraine is associated with a higher burden
of PS. Since the material was not entirely representative of the general population of migraineurs, caution should be
exercised in generalizing the results.
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Introduction
Migraine is the most common neurological disease and is
characterized by intermittent headache accompanied by
nausea, vomiting, photophobia, and phonophobia (1).
The premonitory symptoms (PS) of migraine are defined
in the International Classification of Headache Disorders,
3rd edition (ICHD-III beta), as ‘‘symptoms preceding and
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Neuroscience, Umeå University Hospital, 901 85 Umeå, Sweden.
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forewarning of a migraine attack by 2–48 hours, occur-
ring before the aura in migraine with aura and before the
onset of pain in migraine without aura,’’ with fatigue,
elation, depression, unusual hunger, and craving for cer-
tain foods given as examples (1). However, various PS
and timespans have been used in previous studies (2–8).
The pathophysiologic basis to the PS is incompletely
understood, but the involvement of hypothalamic and
dopaminergic mechanisms has been suggested (9,10).
Recently, glyceryl trinitrate has been used to provoke
migraine-like attacks as well as PS, allowing them to be
studied directly, which might increase our insight into
the pathophysiology of migraine (11,12).
Previous studies have reported that between 8% and
87% of adult migraineurs (4–7) and 67% of child
migraineurs (8) experience PS. Varying study popula-
tions and definitions of PS might have contributed to
the wide range of reported frequencies.
In a prospective study, it was shown that, in migrain-
eurs with PS, the onset of headache attacks can be pre-
dicted several hours in advance (3). Early treatment
guided by PS might be beneficial (13,14).
Our objectives were to determine the frequency and
number of PS among persons from Finnish migraine
families, to explore the co-occurrence of different PS,
and to examine the association between PS and age,
gender, and migraine characteristics.
Methods
We employed a cross-sectional design, using the vali-
dated Finnish Migraine Specific Questionnaire for
Family Studies (15), which was issued in connection
to genetic studies, to obtain data on PS, migraine diag-
noses, demographic factors, and migraine characteris-
tics among migraineurs in Finnish migraine families.
Migraine patients seen by neurologists at outpatient
headache clinics in six Finnish cities with at least three
first-degree relatives with possible migraine were invited
to participate in the study. Those who accepted received
the validated questionnaire, as did their affected relatives
and the first-degree relatives of any affected individual.
The relatives, however, were not seen by a neurologist
and had no physical examination.
The headache diagnoses were based on the ICHD cri-
teria (1) for migraine and consisted of migraine without
aura (MwoA) and migraine with aura (MwA), with the
subtypes being typical aura with migraine headache, typ-
ical aura with non-migraine headache, typical aura with-
out headache, and hemiplegic migraine. Headaches not
fulfilling any of these criteria were denominated as non-
migraine headaches. Participants were recruited between
January 2002 and March 2013 and the study size was
determined by the number of participants during this
period (n¼ 2714).
The 14 predefined PS in the questionnaire were
based on previous studies and selected according to
consensus in the research group (Figure 1). The partici-
pants were asked if some of the symptoms repeatedly
preceded the headache attacks without any specified
time window, giving a binary response for every symp-
tom. The questionnaire also covered headache fre-
quency, duration and intensity, associated symptoms
of the headache phase (unilaterality of headache, pul-
sating headache, aggravation by physical activity,
nausea and/or vomiting, photophobia, and phonopho-
bia), aura symptoms (photopsia, blurring of vision,
visual field defect, scintillating scotoma, hemiparesis,
hemisensory aura, and speech aura), and disability
(working capacity and lifetime number of attacks
requiring bed rest). Demographic factors consisted of
age and gender. Age was divided into four groups for
group analysis: 5–17, 18–40, 41–65, and above 65 years.
A composite variable, ‘‘sum of associated symp-
toms’’, was created by adding together the associated
symptoms, forming groups of persons with 0–2, 3, 4, 5,
and 6 symptoms. The outcomes were the frequency of
PS (i.e. the proportion of persons that experienced at
least one PS) and the total number of PS per person.
Statistical analyses
Statistical analyses were performed using SPSS version
22.0.0. Numerical data were analyzed using the
Kruskal–Wallis test and the Mann–Whitney U test
due to non-normality. Categorical data were analyzed
using the 2 test. The co-occurrence of PS was tested
using Cohen’s kappa with 95% confidence intervals
(CI). A two-sided p-value< 0.05 was considered statis-
tically significant. The p-values were not adjusted for
multiplicity. In the case of missing data, the person was
excluded from analyses involving that variable.
For the binary multiple logistic regression, we
considered age, gender, self-rated working capacity,
headache characteristics (frequency, duration, inten-
sity, unilaterality, pulsating headache, nausea and/or
vomiting, photophobia, and phonophobia), and aura
symptoms to be valid predictors. The dependent vari-
able was the presence of any PS. The following vari-
ables were not considered to be valid predictors:
diagnosis, as their criteria were included in the analysis;
aggravation by physical activity, due to the large
number of missing data; and lifetime number of attacks
requiring bed rest, in order to reduce the number of
categorical variables. Non-significant predictors were
removed one by one from the model, except for age
and gender, which were kept to ensure adequate con-
trolling for these variables. Multicollinearity was tested
with a tolerance value threshold of 0.1. Correlations
between predictors were tested using Spearman’s rank
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correlation and only one of any strongly correlated
(rs> 0.8) predictors was included. Nagelkerke R
2 was
used to evaluate the goodness of fit.
A generalized multiple linear model with a negative
binomial distribution with a log link function was used
for the regression analysis of the number of PS, as it
was determined to be the best fit for our data that
severely deviated from normality. Valid predictors
were the same as for the logistic regression, as was
the procedure for creating the model.
Standard protocol approvals,
registrations, and patient consent
The ethical committee of Helsinki University Central
Hospital approved the study. The responders gave
their informed consent to participate in the study.
Each participant was assigned an individual identifier
and the data were anonymized.
Results
In total, data were collected from 2714 persons, of
whom 2223 fulfilled different migraine criteria. Four
persons received the diagnosis of typical aura without
headache and were excluded from all analyses except
for the comparison between migraine and non-migraine
headaches. Thus, the migraine sample consisted of 2219
persons (475 males and 1744 females, mean age 45
years, SD 17, range 5–96), of whom 1188 fulfilled the
MwA criterion and 1031 fulfilled the MwoA criterion.
A total of 137 persons (62 males and 75 females) were
aged 5–17 years (mean 13 years, SD 3). Of the 491
persons who had non-migraine headaches, 206 were
males and 284 were females, with a mean age of 41
years (SD 20, range 6–88 years). We did not track the
number of questionnaires sent out, but estimate that
the number was 3400. As we received 2714 completed
questionnaires, we estimate that the response rate was
approximately 80%.
Among migraineurs, 77% reported one or more PS
with a mean number of 3.0 (SD 2.9) different symptoms
compared to 30% (p< 0.001) and 0.5 symptoms
(p< 0.001) among those with non-migraine headaches
(Table 1).
Yawning, mood change, and lethargy were the most
common PS, each affecting about one third of all
migraineurs (Figure 1).
Figure 2 shows the distribution of the number of
symptoms experienced per person. Only 9% experi-
enced more than seven PS (Figure 2).
Compared with persons with MwoA, those with
MwA experienced PS slightly more frequently (79%
vs. 75%) and reported a higher number of PS (mean
3.3 vs. 2.7) (p< 0.05) (Table 1). Among the subtypes of
MwA, hemiplegic migraine was associated with the
highest frequency (93%) and number of PS (mean
5.0), and typical aura with non-migraine headache















Figure 1. The frequency of individual premonitory symptoms among migraineurs (n¼ 2219).
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Diagnosis Any migraine 2223 77 3.0 (2.9)
nmHA 491 30 <0.001 0.5 (1.0) <0.001
Diagnosis MwA 1188 79 3.3 (3.0)
MwoA 1031 75 0.033 2.7 (2.7) <0.001
Sub-diagnosis MwA1.2.1 824 82 3.2 (2.8)
AwHA 133 41 0.8 (1.4)
HM 231 93 <0.001 5.0 (3.4) <0.001
Gender Female 1744 81 3.3 (3.0)
Male 475 64 <0.001 1.8 (2.3) <0.001
Age 5–17 137 71 1.9 (2.0)
18–40 730 77 3.0 (2.9)
41–65 1097 78 3.2 (3.0)
>65 254 78 0.25 2.8 (2.8) <0.001
Missing 1
HA frequency <10 94 60 1.6 (1.8)
10–50 338 63 1.7 (2.1)
50–100 351 72 2.2 (2.4)
>100 1425 83 <0.001 3.6 (3.1) <0.001
Missing 11
HA duration <4 h 354 62 1.7 (2.0)
4–72 h 1554 79 3.0 (2.8)
>72 h 251 92 <0.001 5.2 (3.2) <0.001
Missing 60
HA intensity Mild 159 56 1.5 (2.0)
Moderate 780 73 2.4 (2.5)
Severe 980 81 3.3 (2.9)
Unbearable 294 88 <0.001 4.6 (3.4) <0.001
Missing 6
Working capacity Normal 335 58 1.4 (1.8)
Working more difficult 1230 80 3.2 (2.9)
Not able to work 604 84 <0.001 3.7 (3.2) <0.001
Missing 50
Attacks requiring bedrest Never 68 50 1.1 (1.5)
<5 213 60 1.6 (2.0)
5–10 296 68 1.9 (2.1)
10–50 412 71 2.0 (2.2)
50–100 415 84 3.3 (2.8)
>100 640 89 <0.001 4.4 (3.2) <0.001
Missing 175
Unilaterality of HA Yes 1484 82 3.4 (3.0)
No 661 68 <0.001 2.2 (2.6) <0.001
Missing 74
Pulsating HA Yes 1235 80 3.2 (2.9)
No 876 75 0.011 2.8 (2.9) <0.001
Missing 108
Aggravation by physical activity Yes 1639 82 3.4 (3.0)
(continued)
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was associated with the lowest frequency and number
of PS (41%; mean 0.8) (p< 0.001). Females reported PS
more frequently and with a higher number of different
symptoms than males (Table 1). The frequency of PS in
different age groups did not differ significantly
(p¼ 0.25), but the difference in the number of different










No 252 67 <0.001 2.0 (2.4) <0.001
Missing 328
Nausea/vomiting Yes 1989 79 3.2 (2.9)
No 202 61 <0.001 1.4 (1.9) <0.001
Missing 28
Photophobia Yes 2094 79 3.1 (2.9)
No 106 56 <0.001 1.1 (1.5) <0.001
Missing 19
Phonophobia Yes 1886 82 3.3 (2.9)
No 285 54 <0.001 1.2 (1.7) <0.001
Missing 48
Sum of associated symptoms 0–2 54 50 0.8 (1.0)
3 134 66 1.8 (2.5)
4 290 71 2.1 (2.5)
5 666 81 3.3 (2.9)
6 615 90 <0.001 4.2 (3.0) <0.001
Missing 460
nmHA: non-migraine headache; MwA: migraine with aura; MwoA: migraine without aura; AwHA: typical aura with non-migraine headache; HM:
hemiplegic migraine; MwA1.2.1: typical aura with migraine headache; HA: headache; associated symptoms: unilaterality of headache, pulsating headache,































Figure 2. The number of premonitory symptoms experienced per person among migraineurs (n¼ 2219).
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Higher levels of headache frequency, headache dur-
ation, headache intensity, working capacity, and lifetime
number of attacks requiring bed rest were all associated
with a higher frequency and number of PS (Table 1).
All of the associated symptoms of the headache
phase (unilaterality of headache, pulsating headache,
aggravation by physical activity, nausea and/or vomit-
ing, photophobia, and phonophobia) were individually
associated with a higher frequency and number of PS
(Table 1). When adding together the associated symp-
toms, the frequency and number of PS increased with
the number of symptoms.
The PS with the highest co-occurrence were light and
sound sensitivity (kappa¼ 0.51, 95% CI 0.47–0.55),
yawning and lethargy (kappa¼ 0.42, 95% CI 0.38–
0.46), as well as mood change and restlessness
(kappa¼ 0.39, 95% CI 0.35–0.43) (Table 2).
In the binary logistic regression, age, headache dur-
ation, headache intensity, unilaterality, phonophobia,
photopsia, blurring of vision, hemisensory aura, and
speech aura were associated with an increased probabil-
ity of the presence of any PS, while scintillating scotoma
was associated with a decreased probability of the pres-
ence of any PS (Table 3). Age increased the odds of
experiencing PS by 1.0% (95% CI 0.3–1.7%) per year
(p¼ 0.005). Gender was not significantly associated with
the presence of PS. The model was significant when
tested against a constant-only model (2(14)¼ 289.3,
p< 0.001). The correct prediction rate was 79.4%
(96.5% for the presence and 16.5% for the absence)
compared to 78.6% for the constant-only model.
Nagelkerke R2 was 0.213. Due to missing observations,
1959 valid observations were used in the analysis.
In the generalized linear model, age, gender, head-
ache frequency, headache duration, headache intensity,
working capacity, unilaterality, nausea and/or vomit-
ing, phonophobia, photopsia, blurring of vision, hemi-
sensory aura, and speech aura were associated with an
increased number of PS, while scintillating scotoma was
associated with a decreased number of PS (Table 3).
For instance, age increased the number of PS by
0.5% (95% CI 0.3–0.7%) per year (p< 0.001). The
model was significant when tested against the null
model (likelihood ratio 2(21)¼ 756.5, p< 0.001, devi-
ance/df¼ 1,21). Due to missing observations, 1911
valid observations were used in the analysis.
Discussion
This study is, to date, the largest study of PS, including
altogether 2714 persons with headache. The frequency
of PS of 77% among migraineurs in this material is
within the previously reported range of 8–87% (4–7),
comparable to the frequency found in 100 persons seek-
ing a general practitioner for migraine headache (84%)
(5) and 374 migraine patients from a neurology out-
patient clinic (87%) (7), but higher than in a study of
484 migraineurs in the general population (8%) (4) and
893 at a tertiary care clinic (33%) (6). Among the 137
persons below 18 years of age, the frequency of PS was
71%, which is in line with a previous report of 67% in
103 pediatric–adolescent migraine patients (8).
The mean number of different PS per person of 3.0
out of a possible 14 is similar to a previously reported
mean of 3.2 symptoms out of 12 (7).
The most commonly reported individual symptoms
in the present study, namely yawning, mood changes,
Table 2. Kappa coefficients for the co-occurrence of premonitory symptoms (n¼ 2219).
EE RS CG TT YG MC DF LY LS SS FC SG EA
Excess energy (EE)
Restlessness (RS) 0.19
Craving (CG) 0.21 0.22
Thirst (TT) 0.13 0.15 0.16
Yawning (YG) 0.14 0.26 0.36 0.11
Mood change (MC) 0.17 0.39 0.29 0.12 0.33
Difficulties in focusing vision (DF) 0.09 0.25 0.13 0.14 0.16 0.17
Lethargy (LY) 0.15 0.22 0.27 0.14 0.42 0.30 0.15
Light sensitivity (LS) 0.10 0.21 0.17 0.09 0.17 0.25 0.25 0.21
Sound sensitivity (SS) 0.17 0.29 0.24 0.11 0.22 0.30 0.27 0.25 0.51
Feeling cold (FC) 0.17 0.24 0.27 0.16 0.31 0.25 0.16 0.31 0.18 0.21
Sweating (SG) 0.15 0.22 0.10 0.22 0.14 0.16 0.14 0.16 0.14 0.19 0.19
Edema (EA) 0.16 0.14 0.19 0.20 0.15 0.16 0.11 0.12 0.10 0.16 0.15 0.18
Neck symptoms 0.13 0.20 0.22 0.08 0.22 0.23 0.12 0.23 0.16 0.16 0.17 0.11 0.13
The highest values are shown in bold.
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lethargy, neck symptoms, and light sensitivity, have all
previously been shown to be frequent, with some vari-
ation between studies (3,5–8).
As expected, PS were more than twice as common in
migraine headaches as in non-migraine headaches.
Persons with MwA reported PS significantly more
often and experienced a higher number of PS compared
to those with MwoA, which has not been reported pre-
viously (4,5,7,8). The differences were much larger
between the subtypes of MwA, with hemiplegic migraine
having by far the highest frequency and number of PS.
This is in agreement with hemiplegic migraine being at
the very end of the spectrum of migraine severity.
Sound and light sensitivity showed the highest
co-occurrence, which might represent a common origin,
as both symptoms are aspects of sensory hypersensitivity.
Yawning showed a high co-occurrence with several other
symptoms; for instance, lethargy, craving, and mood
changes. In a previous study exploring co-occurrences
of PS, associations between these symptoms were not
as strong as those between depression and irritability,
concentration problems, and fatigue (7).
All measures of severity (frequency, duration, inten-
sity, working capacity, attacks requiring bed rest, and
presence of associated symptoms) were related to a
higher burden of PS. This is in accordance with clinical
impressions and previous findings that severe pain is
associated with a higher number of PS than mild–mod-
erate pain (5) and that those who experience PS have a
longer duration of headache and more nausea (i.e. more
Table 3. Predictors in the regression analyses.
Predictor Odds ratioa (95% CI) p-value EXP (b) (95% CI) p-value
Age 1.010 (1.003–1.017) 0.005 1.005 (1.003–1.007) <0.001
Gender, female 1.28 (0.98–1.69) 0.076 1.16 (1.04–1.29) <0.007
Headache frequency c <0.001
<10 c 0.76 (0.59–0.96) 0.024
10–50 c 0.74 (0.65–0.84) <0.001
50–100 c 0.82 (0.73–0.91) <0.001
>100 c 1.00 (reference)
Headache duration 0.002 <0.001
<4 h 0.69 (0.51–0.93) 0.015 0.86 (0.75–0.98) <0.021
4–72 h 1.00 (reference) 1.00 (reference)
>72 h 1.83 (1.08–3.08) 0.024 1.30 (1.17–1.44) <0.001
Headache intensity 0.032 <0.003
Mild 0.59 (0.38–0.92) 0.021 0.83 (0.68–1.02) 0.074
Moderate 0.83 (0.64–1.08) 0.165 0.92 (0.84–1.00) 0.060
Severe 1.00 (reference) 1.00 (reference)
Unbearable 1.29 (0.82–2.01) 0.268 1.19 (1.07–1.32) <0.002
Working capacity c <0.013
Normal c 0.78 (0.68–0.90) <0.001
Working more difficult c 1.00 (reference)
Not able to work c 0.94 (0.86–1.03) 0.179
Unilaterality 1.38 (1.07–1.77) 0.012 1.10 (1.00–1.20) 0.046
Nausea and/or vomiting c 1.35 (1.15–1.59) <0.001
Photophobia c 1.23 (0.96–1.58) 0.097
Phonophobia 2.30 (1.71–3.10) <0.001 1.61 (1.38–1.87) <0.001
Scintillating scotoma 0.73 (0.57–0.94) 0.015 0.91 (0.84–0.98) 0.015
Photopsia 1.63 (1.21–2.20) 0.001 1.24 (1.14–1.34) <0.001
Blurring of vision 1.64 (1.18–2.27) 0.003 1.14 (1.05–1.24) 0.002
Hemisensory aura 1.81 (1.31–2.51) <0.001 1.17 (1.08–1.28) <0.001
Speech aura 2.21 (1.54–3.17) <0.001 1.53 (1.40–1.67) <0.001
aLogistic regression (n¼ 1959).
bGeneralized linear model (n¼ 1911).
cNot included in the model.
dExp (b) is the exponent.
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is more in migraine) (6). These factors also significantly
and greatly affected the PS as predictors in the regression
analyses. An unpredicted exception was that scintillating
scotoma was associated with a lesser burden of PS.
In this material, a relatively large number of partici-
pants reported a typical headache duration of less than
4 hours. This may be due to the large number of chil-
dren (in whom a shorter duration is more common)
(16), the effects of successful treatment, or the uncer-
tainty of self-reported time estimates. In addition, the
ICHD criteria for MwA do not include a minimum
duration (1).
The number of PS differed across age groups and age
was a significant predictor in both regression analyses.
Previously, in smaller studies, age has not been asso-
ciated with PS (5,7,8).
As in this study, females have been associated with a
higher number of PS previously (7), while there have
been no gender differences in other studies (4–6,8). In
the generalized linear model, females reported a 16%
higher number of PS. Females have a higher prevalence
of migraine and more severe migraines than males (17),
thus our findings might be explained by a stronger
migraine phenotype in females.
Strengths of the study include the vast material, the
large pediatric–adolescent subset, and ample informa-
tion on other characteristics of the migraines.
In terms of the limitations of the study, firstly, the
material did not represent the general population
because the questionnaire was only distributed to
migraine patients and their relatives. While the study
population did consist of persons from a wide range of
ages with both genders being well represented, our sam-
pling strategy caused the material to be skewed towards
those with a larger hereditary burden and more severe
migraine, which was shown in that MwA was more
common than MwoA and in that hemiplegic migraine
was considerably more prevalent than expected, at
approximately one-tenth of all migraineurs compared
to an estimated 1 in 10,000 in the general population
(18). However, this allowed us to study the relationship
between PS and measurements of migraine severity
across their entire range.
Secondly, retrospective questions have the drawback
of potential recall bias and lack the prospective recordings
of the frequency and temporal aspects of the symptoms.
We did not determine the frequency of the symptoms we
considered to be PS during headache-free intervals, which
is more readily done with a prospective approach, and
this might have led to an overestimation of their rate, as
several such symptoms have been shown also to be
common outside the migraine attack (5).
Furthermore, all of the PS in the study were prede-
fined, which could result in a lower reported frequency
than with open questions in which participants are able
to add their other observed symptoms. For instance,
‘‘face changes’’, which in a previous report was the
most common individual PS among children, was not
included (8). However, open questions might have
introduced unspecific symptoms and been unfavorable
for determining co-occurrences.
In conclusion, PS are experienced by a majority of
migraineurs, more commonly in females. A higher
burden of PS is associated with a more severe migraine.
Thus, further understanding of the pathophysiology of
the premonitory phase is desired to enable the develop-
ment of specific therapy for this early phase of migraine
that might alleviate the subsequent attack.
Clinical implications
. Increased knowledge of the occurrence of premonitory symptoms (PS) could help in understanding the
pathophysiologic basis of migraine.
. Among 2223 individuals with migraine, 77% reported PS.
. More severe migraine was associated with a higher burden of PS.
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Lars Söderström, statistician at the Unit of Research,
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